Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study

被引:210
作者
el Moussaoui, Rachida
de Borgie, Corianne A. J. M.
van den Broek, Peterhans
Hustinx, Willem N.
Bresser, Paul
van den Berk, Guido E. L.
Poley, Jan-Werner
van den Berg, Bob
Krouwels, Frans H.
Bonten, Marc J. M.
Weenink, Carla
Bossuyt, Patrick M. M.
Speelman, Peter
Opmeer, Brent C.
Prins, Jan M.
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[3] Leiden Univ, Med Ctr, Dept Internal Med, Leiden, Netherlands
[4] Diaconessenhuis, Dept Internal Med, Utrecht, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands
[6] Onze Lieve Vrouw Hosp, Dept Internal Med, Amsterdam, Netherlands
[7] St Lucas Andreas Hosp, Dept Internal Med, Amsterdam, Netherlands
[8] St Lucas Andreas Hosp, Dept Pulmonol, Amsterdam, Netherlands
[9] Onze Lieve Vrouw Hosp, Dept Pulmonol, Amsterdam, Netherlands
[10] Univ Med Ctr Utrecht, Dept Internal Med, Utrecht, Netherlands
[11] Kennemer Gasthuis, Dept Pulmonol, Haarlem, Netherlands
来源
BMJ-BRITISH MEDICAL JOURNAL | 2006年 / 332卷 / 7554期
关键词
D O I
10.1136/bmj.332.7554.1355
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To compare the effectiveness of discontinuing treatment with amoxicillin after three days or eight days in adults admitted to hospital with mild to moderate-severe community acquired pneumonia who substantially improved after an initial three days' treatment. Design Randomised, double blind, placebo controlled non-inferiority trial. Setting Nine secondary and tertiary care hospitals in the Netherlands. Participants Adults with mild to moderate-severe community acquired pneumonia (pneumonia severity index score <= 110). Interventions Patients who had substantially improved after three days' treatment with intravenous amoxicillin were randomly assigned to oral amoxicillin (n = 63) or placebo (n = 56) three times daily for five days. Main outcome measures The primary outcome measure was the clinical success rate at day 10. Secondary outcome measures were the clinical success rate at day 28, symptom resolution, radiological success rates at days 10 and 28, and adverse events. Results Baseline characteristics were comparable, with the exception of symptom severity, which was worse in the three day treatment group. In the three day and eight day treatment groups the clinical success rate at day 10 was 93% for both (difference 0.1%, 95% confidence interval - 9% to 10%) and at day 28 was 90% compared with 88% (difference 2.0%, - 9% to 15%). Both groups had similar resolution of symptoms. Radiological success rates were 86% compared with 83% at day 10 (difference 3%, - 10% to 16%) and 86% compared with 79% at day 28 (difference 6%, - 7% to 20%). Six patients (11%) in the placebo group and 13 patients (21%) in the active treatment group reported adverse events (P = 0.1). Conclusions Discontinuing amoxicillin treatment after three days is not inferior to discontinuing it after eight days in adults admitted to hospital with mild to moderate-severe community acquired pneumonia who substantially improved after an initial three days' treatment.
引用
收藏
页码:1355 / 1358
页数:4
相关论文
共 13 条
  • [1] Awasthi S, 2004, BMJ-BRIT MED J, V328, P791
  • [2] CHOW AW, 1992, CLIN INFECT DIS S1, V15, P62
  • [3] High-dose, short-course Levofloxacin for community-acquired pneumonia: A new treatment paradigm
    Dunbar, LM
    Wunderink, RG
    Habib, MP
    Smith, LG
    Tennenberg, AM
    Khashab, MM
    Wiesinger, BA
    Xiang, JX
    Zadeikis, N
    Kahn, JB
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (06) : 752 - 760
  • [4] Development and validation of a short questionnaire in community acquired pneumonia
    El Moussaoui, R
    Opmeer, BC
    Bossuyt, PMM
    Speelman, P
    de Borgie, CAJM
    Prins, JM
    [J]. THORAX, 2004, 59 (07) : 591 - 595
  • [5] The Alexander Project 1996-1997:: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
    Felmingham, D
    Grüneberg, RN
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) : 191 - 203
  • [6] Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment
    Finch, R
    Schürmann, D
    Collins, O
    Kubin, R
    McGivern, J
    Bobbaers, H
    Izquierdo, JL
    Nikolaides, P
    Ogundare, F
    Raz, R
    Zuck, P
    Hoeffken, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) : 1746 - 1754
  • [7] A prediction rule to identify low-risk patients with community-acquired pneumonia
    Fine, MJ
    Auble, TE
    Yealy, DM
    Hanusa, BH
    Weissfeld, LA
    Singer, DE
    Coley, CM
    Marrie, TJ
    Kapoor, WN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (04) : 243 - 250
  • [8] Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia
    Hagberg, L
    Torres, A
    van Rensburg, D
    Leroy, B
    Rangaraju, M
    Ruuth, E
    [J]. INFECTION, 2002, 30 (06) : 378 - 386
  • [9] Hazir T, 2002, LANCET, V360, P835
  • [10] A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults
    Ortiz-Ruiz, G
    Caballero-Lopez, J
    Friedland, IR
    Woods, GL
    Carides, A
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (08) : 1076 - 1083